Agreement signed with major cancer center to profile patients in immuno-oncology trial (Copia Digital)
“Oncimmune Holdings plc…announces it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute…Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTagTM, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors (‘CPIs’) and chemotherapy used in Dana-Farber led studies or therapy using atezolizumab, nivolumab, pembrolizumab, durvalumab and cisplatin-based chemotherapy. In addition, SeroTag will be used for identifying autoantibodies that can be predictive of immune-related adverse events ‘irAEs’) in response treatment. The project is scheduled to complete by the end of 2021.”